Movement Alert|IDEXX Laboratories Intraday Rise 3.04% in Regular Trading, Q3 beat and raised full-year outlook continued to support shares

Market Focus11-10

On November 10, IDEXX Laboratories recorded an Intraday Rise of 3.04% in Regular Trading, trading around $697.25, with turnover of $168 million.

The move was supported by the company’s previously reported third-quarter results that exceeded market expectations and by a higher full-year outlook.

IDEXX Laboratories reported third-quarter comparable EPS of $3.96 on revenue of $1.21 billion, above consensus expectations of $3.73 and $1.19 billion, respectively. The company also raised its full-year comparable EPS growth outlook to 15% to 16% from 13% to 15%, and lifted revenue guidance to $4.74 billion to $4.77 billion from $4.70 billion to $4.75 billion. Additional follow-through came from analysts highlighting resilient pricing despite softer veterinary visit trends, while a major broker also raised its price target to $800 from $740 shortly after the results.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment